Transposagen's expanded license with the University of Notre Dame, University of Florida, and the USDA will cover nearly all commercial applications, including as a tool for drug and biomarker discovery.
Under the Phenotypic Drug Discovery program, researchers from academia or biotech submit candidate compounds in specific therapeutic areas for Lilly to evaluate and profile. Participating organizations retain full IP rights to the compounds, but Lilly receives first rights to negotiate a broader collaboration or licensing agreement.
Eli Lilly, Cornell University, and the Kauffman Foundation's iBridge Network each unveiled web-based initiatives for facilitating tech transfer at last week's Association of University Technology Managers annual meeting.
In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.